Home Kontakt Sitemap

WILEX AG

Unternehmen

Portfolio

Partner

Technologien

Presse + Investoren

Karriere

Investigational New Drug (IND)

Genehmigungsantrag für die Durchführung von klinischen Studien in den USA

Print This Post

Print This Post |

Email This Post

Email This Post

Seite gelesen: 131 | Heute: 3

Seite gelesen: 132 | Heute: 2

Overview
WILEX subsidiaries
Management Team
Supervisory Board
Medical Advisory Board
History
Contact
Facility

Pipeline
Philosophy
RENCAREX®
REDECTANE®
MESUPRON®
WX-554
WX-037
Research Projects
Publications
For Patients

Cooperations
Commercialisation

TECHNOLOGIES

Antibodies
Small molecules
ADC-Technology
Diagnostics

PRESS + INVESTORS

Strategy
Facts
Share
Announcements
Financial reports
Presentations
Annual General Meeting
Corporate Governance
Financial Calendar
Conferences
Annual Document
IR Service
IR/PR Contact
Pressphotos

WILEX AG - Focused Cancer Therapies | Grillparzerstr. 10, 81675 Munich | Germany | Tel. +49 (0)89 41 31 38 - 0 | Fax +49 (0)89 41 31 38 - 99

Imprint | Disclaimer | Privacy Policy © WILEX AG | RENCAREX®, REDECTANE® and MESUPRON® are registered trademarks.